PTPRC and acute myeloid leukemia: Unfortunately, only about 50% of AML cases have clonal chromosome markers to allow easy distinction, but other aberrant leukemic cell phenotypes can sometimes allow the distinction of normal vs. leukemia human CD45+ cells to be made by flow cytometry or by mutation analysis by PCR or sequencing.